Kåre Schultz

Kåre Schultz has been an Advisor to EQT since 2023.

Kåre is a Danish business executive. He was the President & CEO of Teva Pharmaceutical Industries between September 2017 and December 2022 where he led a major restructuring of the company, addressing declining revenue and large debt. From 2015 to 2017, Kåre served as the President & CEO of H. Lundbeck A/S where he carried out a company-wide restructuring caused by patent loss and declining revenue. Prior to joining Lundbeck, he worked for nearly three decades at Novo Nordisk, where he served in several leadership roles, including Chief Operating Officer, Vice President in Product Supply and Director of Product Planning and Customer Services in the Diabetes Care Division. At Novo Nordisk, Kåre played a major role in modernizing the company’s large scale biologic production and leading the company’s expansion into the US and Chinese markets. In addition to his time at Novo Nordisk, he has held positions at McKinsey and Anderson Consulting.

Kåre has served on a variety of Boards during his career including International Flavors and Fragrances Inc., Royal Unibrew A/S, LEGO A/S, and is currently the Chairman of the Board of Scandinavian Airlines, Bespak, Azelis and Karo Healthcare as well as a member of the board of Hims & Hers Health, Inc. He is also Senior Advisor to A.P. Møller Holding A/S and Advent International.

He holds a master’s degree in Economics from the University of Copenhagen

EQT Board Memberships

Current:
Chairperson of Azelis, Bespak and Karo Healthcare

Former:
Board Member of Azelis